Treatment and surgery of primary hepatic cancer with portal vengus tumor thrombosis.
- Author:
Yu-bin LIU
1
;
Zhi-xiang JIAN
;
Jin-rui OU
;
Zi-xian LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Hepatocellular; mortality; pathology; surgery; therapy; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Hepatectomy; methods; Humans; Liver Neoplasms; mortality; pathology; surgery; therapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Portal Vein; pathology; Retrospective Studies; Survival Rate
- From: Chinese Journal of Surgery 2005;43(7):436-438
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the methods of surgery for hepatocellular carcinoma (HCC) with tumor thrombi in portal vein (TTPV).
METHODSTo Analyze and summarize the clinical information from 138 HCC patients with tumor thrombi in portal vein collected during January 1990 and January 2003.
RESULTSThirty-seven patients receiving palliative therapy died from 1 to 8 months, and average survival time is 3.9 months. 101 patients had operation treatment, 23 of them underwent hepatoma resection, and average survival time was 10.9 months; 78 patients underwent hepatoma resection and removal of tumor thrombi, and average survival time was 26.8 months. 52 of whom underwent hepatic artery and portal vein chemoembolization, the 1-, 3-, 5-year survival rates was 96.2%, 51.9%, 11.5%, the 1-, 3-, 5-year survival rates of the 26 patients who didn't undergo chemoembolization were 76.9%, 23.1%, 0%.
CONCLUSIONSOperation treatment can comparatively extend the survival time of hepatocellular carcinoma with tumor thrombi in portal vein patients, and the best choice is hepatoma resection and removal of tumor thrombi, hepatic artery and portal vein chemoembolization after operation can enhance the effect.
